<DOC>
	<DOCNO>NCT01734382</DOCNO>
	<brief_summary>PART1 Participants Part 1 ( Run-in-Phase ) study receive Tocilizumab ( TCZ ) ( RoActemra/Actemra ) 12 milligram per kilogram ( mg/kg ) 8 mg/kg intravenously ( IV ) every 2 week ( Q2W ) 24 week . Participants experience laboratory abnormality part 1 may eligible move Part 2 study . PART 2 This open-label Phase IV study evaluate efficacy , safety , pharmacokinetics , pharmacodynamics immunogenicity RoActemra/Actemra ( tocilizumab ) reduce dose frequency participant adequately control systemic juvenile idiopathic arthritis experience laboratory abnormality twice weekly RoActemra/Actemra dosing , since resolve . Participants receive RoActemra/Actemra 12 mg/kg 8 mg/kg intravenously every 3 week . After 5 consecutive infusion , participant experience event neutropenia , thrombocytopenia liver enzyme abnormality move every 4 week RoActemra/Actemra administration . Anticipated time study treatment 52 week .</brief_summary>
	<brief_title>A Study Decreased Dose Frequency Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra ( Tocilizumab )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>PART 1 2 Children 2 17 year age inclusive screen Systemic juvenile idiopathic arthritis ( sJIA ) accord International League Associations Rheumatology ( ILAR ) classification ( 2001 ) sJIA symptom last least 1 month since diagnosis sJIA Must meet one follow : Not receive methotrexate ( MTX ) discontinue MTX least 4 week prior baseline visit , Taking MTX least 12 week immediately prior baseline visit stable dose less equal ( &lt; /= ) 20 milligram per meter square ( mg/m^2 ) least 8 week prior baseline visit , together either folic acid folinic acid accord local standard care Participants enter Part 1 naive TCZ therapy must also meet follow inclusion criterion : History inadequate clinical response ( opinion treat physician ) Non steroidal AntiInflammatory Drugs ( NSAIDs ) corticosteroid PART 2 Juvenile Arthritis Disease Activity Score ( JADAS ) 71 score 3.8 less absence fever ( related sJIA ) screen baseline Neutropenia , thrombocytopenia , elevate Alanine transaminase/Aspartate transaminase ( ALT/AST ) previously experience label dose ( Q2W ) RoActemra/Actemra time Not currently receive oral corticosteroid , take oral corticosteroid stable dose minimum 2 week prior baseline visit 10 milligram per day ( mg/day ) 0.2 miiligrams per kilogram per day ( mg/kg/day ) , whichever less Not take ( NSAIDs ) , take 1 type NSAID stable dose minimum 2 week prior baseline visit , dose less equal maximum recommend daily dose Wheelchair bound bedridden Any autoimmune , rheumatic disease , overlap syndrome sJIA Pregnant lactating , intend become pregnant study conduct 6 month last administration study drug Any significant concurrent medical surgical condition would jeopardize participant 's safety ability complete trial History significant allergic infusion reaction prior TCZ infusion , and/or presence antiTCZ antibody screen Inborn condition characterize compromise immune system Known Human Immunodeficiency Virus ( HIV ) infection acquire form immune compromise History alcohol , drug , chemical abuse within 6 month screen Evidence serious uncontrolled concomitant disease , include limited nervous , renal , hepatic , endocrine system Any active acute , subacute , chronic recurrent bacterial , viral , systemic fungal infection History atypical tuberculosis ( TB ) Active TB require treatment within 2 year prior screen visit Positive purify protein derivative ( PPD ) screen Any major episode infection require hospitalization treatment screen treatment IV antibiotic complete within 4 week screen visit oral antibiotic complete within 2 week screen visit History reactivation new onset systemic infection within 2 month screen visit Positive hepatitis B hepatitis C infection Chronic hepatitis , viral pulmonary disease Significant cardiac pulmonary disease History current cancer lymphoma Uncontrolled diabetes mellitus History concurrent serious gastrointestinal disorder History macrophage activation syndrome ( MAS ) within 3 month prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>